Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consolidated CDER/CBER INDs renumbered

Executive Summary

The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...

You may also be interested in...

CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions

FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts